A network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic heart failure
Related Experiment Video
Updated: Dec 25, 2025

Identification of Disease-related Spatial Covariance Patterns using Neuroimaging Data
Published on: June 26, 2013
Iziah E Sama1, Rebecca J Woolley1, Jan F Nauta1
1Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands.
Insights
This study identified key molecular differences between ischaemic and non-ischaemic heart failure (HF). Five proteins involved in inflammation and atherosclerosis pathways were found to be potential therapeutic targets for ischaemic HF.
Area of Science:
- Cardiovascular Biology
- Biomarker Discovery
- Network Medicine
Background:
- Heart failure (HF) arises from ischaemic events or primary cardiomyopathy.
- Understanding molecular distinctions is crucial for targeted therapies in HF.
Purpose of the Study:
- To differentiate molecular mechanisms between ischaemic and non-ischaemic HF.
- To identify novel therapeutic targets for ischaemic heart disease.
Main Methods:
- Protein-protein interaction network analysis of plasma biomarkers from 1160 HF patients.
- Pathway over-representation analysis to identify distinguishing pathophysiological mechanisms.
- Validation in an independent cohort of 865 HF patients.
Main Results:
- Identified 21 up-regulated and 2 down-regulated proteins in ischaemic HF versus non-ischaemic HF.
- Discovered six pathways related to inflammation, endothelial dysfunction, coagulation, and atherosclerosis specific to ischaemic HF.
- Pinpointed five key network proteins: acid phosphatase 5, EGFR, IGFBP1, uPAR, and SPP1.
Conclusions:
- Distinct pathophysiological pathways differentiate ischaemic from non-ischaemic HF.
- The five identified key proteins represent potential therapeutic targets for ischaemic HF treatment.
Aims:
Heart failure (HF) is frequently caused by an ischaemic event (e.g. myocardial infarction) but might also be caused by a primary disease of the myocardium (cardiomyopathy). In order to identify targeted therapies specific for either ischaemic or non-ischaemic HF, it is important to better understand differences in underlying molecular mechanisms.
Methods And Results:
We performed a biological physical protein-protein interaction network analysis to identify pathophysiological pathways distinguishing ischaemic from non-ischaemic HF. First, differentially expressed plasma protein biomarkers were identified in 1160 patients enrolled in the BIOSTAT-CHF study, 715 of whom had ischaemic HF and 445 had non-ischaemic HF. Second, we constructed an enriched physical protein-protein interaction network, followed by a pathway over-representation analysis. Finally, we identified key network proteins. Data were validated in an independent HF cohort comprised of 765 ischaemic and 100 non-ischaemic HF patients. We found 21/92 proteins to be up-regulated and 2/92 down-regulated in ischaemic relative to non-ischaemic HF patients. An enriched network of 18 proteins that were specific for ischaemic heart disease yielded six pathways, which are related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. We identified five key network proteins: acid phosphatase 5, epidermal growth factor receptor, insulin-like growth factor binding protein-1, plasminogen activator urokinase receptor, and secreted phosphoprotein 1. Similar results were observed in the independent validation cohort.
Conclusions:
Pathophysiological pathways distinguishing patients with ischaemic HF from those with non-ischaemic HF were related to inflammation, endothelial dysfunction superoxide production, coagulation, and atherosclerosis. The five key pathway proteins identified are potential treatment targets specifically for patients with ischaemic HF.
More Related Videos
08:51Author Spotlight: Integrated Multi-Omics Analysis for Unveiling Multicellular Immune Signatures in Clinical Heart Attack Cohorts
Published on: September 20, 2024
05:16Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
Related Concept Videos
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure IV: Classification and Diagnostic Evaluation
Heart Failure I: Introduction
Pathophysiology of Cardiac Performance
Coronary Artery Disease II: Pathophysiology